U.S., June 4 -- ClinicalTrials.gov registry received information related to the study (NCT07002203) titled 'Personalized Neoantigen Peptide Vaccines for Solid Tumors' on May 23.
Brief Summary: This clinical trial is studying the safety and efficacy of a personalized cancer vaccine called a neoantigen peptide vaccine in patients with solid tumors. These vaccines are custom-made for each patient using specific mutations (neoantigens) found in their own tumor. The goal is to help the patient's immune system recognize and attack their cancer.
The study will enroll adult patients (20 years or older) who have solid tumors that meet specific stage-related criteria. These include advanced cancers that are resistant to prior treatments and early-s...